Conolidine’s analgesic results stem from its interaction with non-opioid pain pathways. Unlike opioids, which bind to µ-opioid receptors while in the central nervous procedure, conolidine modulates alternate molecular targets. A Science Developments study located that conolidine interacts with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability. By https://yogiw840riz6.wikinstructions.com/user